GlobalData forecasts AbbVie holding strong in immunology

30 January 2019

A report from industry analyst GlobalData suggests that AbbVie’s (NYSE: ABBV) strong immunology pipeline will protect its grip on the plaque psoriasis and rheumatoid arthritis markets, while the workhorse Humira (adalimumab) loses ground to competition in Europe.

GlobalData says Humira biosimilars will take in between $440 million and $2.5 billion in these indications across the seven major markets by 2027.

Analyst Vikesh Devlia said: “AbbVie seems relatively unfazed by the impact of Humira biosimilars on overall sales and has demonstrated that its pipeline for immunology indications remains strong.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK